HLA-DQB1*05 Subtypes and Not DRB1*10:01 Mediates Risk in Anti-Iglon5 Disease

Anti-IgLON5 disease is a rare and likely underdiagnosed subtype of autoimmune encephalitis. The disease displays a heterogeneous phenotype that includes sleep, movement and bulbar-associated dysfunction. The presence of IgLON5-antibodies in CSF/serum, together with a strong association with HLA-DRB1*10:01 similar to DQB1*05:01, supports an autoimmune basis.In this study, a multicentric human leukocyte antigen (HLA) study of 87 anti-IgLON5 patients revealed a stronger association with HLA-DQ than HLA-DR. Specifically, we identified a predisposing rank-wise association with HLA-DQA1*01:05 similar to DQB1*05:01, HLA-DQA1*01:01 similar to DQB1*05:01 and HLA-DQA1*01:04 similar to DQB1*05:03 in 85% of patients. HLA sequences and binding cores for these three DQ heterodimers were similar, unlike those of linked DRB1 alleles, supporting a causal link to HLA-DQ. This association was further reflected in an increasingly later age of onset across each genotype group, with a delay of up to 11 years, while HLA-DQ-dosage dependent effects were also suggested by reduced risk in the presence of non-predisposing DQ1 alleles. The functional relevance of the observed HLA-DQ molecules was studied with competition binding assays. These proof-of-concept experiments revealed preferential binding of IgLON5 in a post-translationally modified, but not native, state to all three risk-associated HLA-DQ receptors. Further, a deamidated peptide from the Ig2-domain of IgLON5 activated T cells in two patients, compared with one control carrying HLA-DQA1*01:05 similar to DQB1*05:01.Taken together, these data support a HLA-DQ-mediated T-cell response to IgLON5 as a potentially key step in the initiation of autoimmunity in this disease. Anti-IgLON5 disease is a rare subtype of autoimmune encephalitis with late onset. Yogeshwar et al. present genetic, clinical, and immune cell phenotyping data suggesting a stronger association with HLA-DQ over HLA-DR, and showing autoimmune reactivity against IgLON5 in a post-translationally modified form.